ArticlePacing and clinical electrophysiology : PACE2026
Outcomes of Functional Substrate Mapping Based Ablation in Addition to Pulmonary Vein Isolation in Atrial Fibrillation.
Article in Pacing and clinical electrophysiology : PACE, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Outcomes of Functional Substrate Mapping Based Ablation in Addition to Pulmonary Vein Isolation in Atrial Fibrillation.Pacing and clinical electrophysiology : PACE · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFunctional substrate mapping (FSM) enables the identification of slow conduction zones, which may represent critical atrial sites in atrial fibrillation (AF). This study aimed to evaluate the efficacy of FSM-guided ablation as an adjunct to pulmonary vein isolation (PVI) and to identify clinical predictors of arrhythmia recurrence in patients with AF.
methodsA total of 206 patients [mean age 61 ± 10, 105 (%51) males] with AF who underwent voltage and isochronal late activation mapping (ILAM) during sinus/paced rhythm were retrospectively included. Patients were divided into two groups based on the presence of deceleration zone (DZ) during ILAM: DZ (-) and DZ (+). While patients in the DZ (-) group underwent PVI alone, those in the DZ (+) group received additional ablation lesions targeting the DZs in addition to PVI.
resultsThe mean number of DZs per left atrium was 1.45 ± 0.6. In the DZ (+) patients, 43 ATs were inducible in 35 patients, with 81.4% (35/43) of CIs colocalized with the DZs identified during ILAM. At a median follow-up of 12.5 (8-23) months, atrial arrhythmia-free survival was significantly higher in the DZ (-) group compared to the DZ (+) group (p = 0.004). Multivariate Cox regression analysis revealed that the presence of DZ (HR: 2.152, 95%CI 1.051-4.404; p = 0.036) was the only significant predictor associated with atrial arrhythmia recurrence.
conclusionsDZs identified by ILAM may serve as a critical substrate for AF and targeting these regions as an adjunct to PVI could improve procedural success especially in PAF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.